Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials
Authors:
- 1 December 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (12) , e2027110
Abstract
The advent of highly active antiretroviral therapy (ART) has revolutionized the treatment of people living with HIV (PLWH), with many expected to have a nearly normal life expectancy.1 Furthermore, the proportion of PLWH in the US aged 65 years or older is projected to increase from 8.5% in 2010 to 21.4% by 2030.2 Cancer is now a leading cause of morbidity and mortality in this population,3 with non–AIDS-defining cancers, such as lung and colon cancer, becoming increasingly prevalent.2,4Keywords
This publication has 19 references indexed in Scilit:
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working GroupJournal of Clinical Oncology, 2017
- Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United StatesJAMA Internal Medicine, 2017
- Faculty Opinions recommendation of Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.2016
- Dynamic Perturbations of the T-Cell Receptor Repertoire in Chronic HIV Infection and following Antiretroviral TherapyFrontiers in Immunology, 2016
- Cumulative Incidence of Cancer Among Persons With HIV in North AmericaAnnals of Internal Medicine, 2015
- Standards for Reporting Qualitative ResearchAcademic Medicine, 2014
- Cancer Treatment Disparities in HIV-Infected Individuals in the United StatesJournal of Clinical Oncology, 2014
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and CanadaPLOS ONE, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012